Introduction.
The increasing number of patients presenting with failed mitral
bioprosthesis is the consequence of the shift from mechanical toward
bioprosthetic valve implantation in the last decade. Even though redo
surgery remains the gold standard, transcatheter mitral valve-in-valve
implantation (TMViV) has emerged as a safe and attractive alternative of
interest for high risk patients.